

MEASUREMENT YEAR 2017 IHA-PBGH COMMERCIAL ACO MEASURE SET

NQF#	Measurement Year 2017/ Reporting Year 2018 Measures	Collection Approach	
		PO Self Report	Vendor Report/ HP Claims Submission
	<u>Cardiovascular</u>		
N/A	1. Statin Therapy for Patients With Cardiovascular Disease	X	X
0018	2. Controlling Blood Pressure for People with Hypertension	X	
	<u>Diabetes</u>		
0057 0061 0059 0062 0055	3. Comprehensive Diabetes Care (HbA1c Testing, Blood Pressure Control <140/90 mm Hg, HbA1c Poor Control > 9.0%, Medical Attention for Nephropathy, Eye Exam)	X	X
N/A	4. Statin Therapy for Patients With Diabetes	X	X
	<u>Musculoskeletal</u>		
0052	5. Use of Imaging Studies for Low Back Pain	X	X
	<u>Prevention & Screening</u>		
2372	6. Breast Cancer Screening	X	X
0033	7. Chlamydia Screening in Women	X	X
0038	8. Childhood Immunization Status: Combination 10	X	X
0034	9. Colorectal Cancer Screening	X	X
0032	10. Cervical Cancer Screening	X	X
0032	11. Cervical Cancer Overscreening	X	X
1407	12. Immunizations for Adolescents: Combination 2	X	X
	<u>Respiratory</u>		
1800	13. Asthma Medication Ratio	X	X
	14. Appropriate Testing of Children with Pharyngitis		
0058	15. Avoidance of Antibiotic Treatment of Adults with Acute Bronchitis	X	X
	<u>Resource Use</u>		
0329	16. All-Cause Readmissions		X
N/A	17. Emergency Department Visits		X
N/A	18. Total Cost of Care		X

Developmental Measures

Recognizing the desire from stakeholders and purchasers to advance more meaningful measures, the IHA-PBGH Commercial ACO measure set includes a number of “developmental” measures that cannot currently be collected using existing VBP4P data collection approaches. The ACO measurement program is well-positioned to develop and implement these progressive and clinically powerful measures that reflect high priority areas for purchasers, opportunities for pioneering measurement as identified by CQMC, and align with the priorities identified for VBP4P in the [2016 – 2021 Measure Set Strategy](#).

To acknowledge and accommodate developmental measures, IHA envisions a phased, multi-year implementation process. The developmental measures are targeted for implementation in years 2, 3, or 4 (MY 2018, MY 2019, and MY 2020, respectively). Measures slated for development and implementation in future years include:

- *Initiation and Engagement of Alcohol and Other Drug Dependence Treatment*
- *Persistent Beta Blocker After Heart Attack*
- *Potentially Avoidable ER Visits*
- *Prenatal and Postpartum Care*
- *Preventative Care & Screening: Tobacco Use Screening & Cessation Intervention*
- *AHRQ Prevention Quality Indicator #90: Ambulatory Sensitive Admissions*
- *Use of Opioids at High Dosage OR Concurrent Use of Opioids & Benzodiazepines*
- *Weight Assessment & Counseling for Nutrition and Physical Activity for Children/Adolescents*
- *CG-CAHPS (ACO)*
- *Patient Reported Outcomes*
- *Flu Vaccinations for Adults 18-64*
- *Adult BMI Screening & Follow Up*
- *Depression Remission at 6 months*
- *Screening for Clinical Depression & Follow Up Plan*
- *Ischemic Vascular Disease: Aspirin Use*
- *Optimal Diabetes Care Combination*
- *NTSV C-Section*